Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
Normal
Figure 4. Effect of recombinant follicle-stimulating hormone (r-FSH) priming followed by r-FSH plus human chorionic gonadotrophin (hCG) treatment on serum anti-Müllerian hormone (AMH), as a Sertoli cell biomarker, and testosterone (T), as a Leydig cell biomarker, in patients with central hypogonadism. Initial r-FSH treatment with 150IU/day for 30days increased Sertoli cell AMH secretion. The addition of hCG resulted in an increase of Leydig cell T secretion, which induced Sertoli cell maturation as reflected in the decline in AMH levels. The grey areas represent normal AMH levels for males with prepubertal T levels, corresponding to pubertal Tanner stage 1, on the left, and to Tanner 4–5 levels on the right. *p<0.05; **p<0.01; ***p<0.001. Modified with permission from Young et al.130 © 2005 The Endocrine Society.[ATTACH=full]19233[/ATTACH]
Figure 4. Effect of recombinant follicle-stimulating hormone (r-FSH) priming followed by r-FSH plus human chorionic gonadotrophin (hCG) treatment on serum anti-Müllerian hormone (AMH), as a Sertoli cell biomarker, and testosterone (T), as a Leydig cell biomarker, in patients with central hypogonadism. Initial r-FSH treatment with 150IU/day for 30days increased Sertoli cell AMH secretion. The addition of hCG resulted in an increase of Leydig cell T secretion, which induced Sertoli cell maturation as reflected in the decline in AMH levels. The grey areas represent normal AMH levels for males with prepubertal T levels, corresponding to pubertal Tanner stage 1, on the left, and to Tanner 4–5 levels on the right. *p<0.05; **p<0.01; ***p<0.001. Modified with permission from Young et al.130 © 2005 The Endocrine Society.
[ATTACH=full]19233[/ATTACH]
We use essential cookies to make this site work, and optional cookies to enhance your experience.
See further information and configure your preferences
